ID   UHRF1_HUMAN             Reviewed;         793 AA.
AC   Q96T88; A0JBR2; A8K024; B2RBA9; Q2HIX7; Q8J022; Q9H6S6; Q9P115;
AC   Q9P1U7;
DT   07-JUN-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   10-MAY-2017, entry version 153.
DE   RecName: Full=E3 ubiquitin-protein ligase UHRF1;
DE            EC=2.3.2.27;
DE   AltName: Full=Inverted CCAAT box-binding protein of 90 kDa;
DE   AltName: Full=Nuclear protein 95;
DE   AltName: Full=Nuclear zinc finger protein Np95;
DE            Short=HuNp95;
DE            Short=hNp95;
DE   AltName: Full=RING finger protein 106;
DE   AltName: Full=RING-type E3 ubiquitin transferase UHRF1;
DE   AltName: Full=Transcription factor ICBP90;
DE   AltName: Full=Ubiquitin-like PHD and RING finger domain-containing protein 1;
DE            Short=hUHRF1;
DE   AltName: Full=Ubiquitin-like-containing PHD and RING finger domains protein 1;
GN   Name=UHRF1; Synonyms=ICBP90, NP95, RNF106;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY,
RP   DEVELOPMENTAL STAGE, SUBCELLULAR LOCATION, DNA-BINDING, INDUCTION, AND
RP   FUNCTION.
RC   TISSUE=Thymus;
RX   PubMed=10646863;
RA   Hopfner R., Mousli M., Jeltsch J.-M., Voulgaris A., Lutz Y., Marin C.,
RA   Bellocq J.-P., Oudet P., Bronner C.;
RT   "ICBP90, a novel human CCAAT binding protein, involved in the
RT   regulation of topoisomerase IIa expression.";
RL   Cancer Res. 60:121-128(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=17067204; DOI=10.1667/RR0459.1;
RA   Muto M., Fujimori A., Nenoi M., Daino K., Matsuda Y., Kuroiwa A.,
RA   Kubo E., Kanari Y., Utsuno M., Tsuji H., Ukai H., Mita K.,
RA   Takahagi M., Tatsumi K.;
RT   "Isolation and characterization of a novel human radiosusceptibility
RT   gene, NP95.";
RL   Radiat. Res. 166:723-733(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Davenport J.W., Fernandes E.R., Neale G.A.M., Goorha R.M.;
RT   "LMO2-induced T cell leukemias overexpress Np95, a gene containing
RT   RING and PHD zinc fingers and an ubiquitin-like domain.";
RL   Submitted (JUN-2000) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS
RP   LYS-379 AND THR-638.
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS HIS-240; LYS-379;
RP   THR-638; MET-642 AND PHE-713.
RG   NIEHS SNPs program;
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   INDUCTION, AND TISSUE SPECIFICITY.
RX   PubMed=12838312; DOI=10.1038/sj.bjc.6601068;
RA   Mousli M., Hopfner R., Abbady A.-Q., Monte D., Jeanblanc M., Oudet P.,
RA   Louis B., Bronner C.;
RT   "ICBP90 belongs to a new family of proteins with an expression that is
RT   deregulated in cancer cells.";
RL   Br. J. Cancer 89:120-127(2003).
RN   [11]
RP   PHOSPHORYLATION, PHOSPHORYLATION AT SER-298, AND MUTAGENESIS OF
RP   SER-298; SER-651 AND SER-666.
RX   PubMed=15178447; DOI=10.1016/j.bbrc.2004.05.028;
RA   Trotzier M.-A., Bronner C., Bathami K., Mathieu E., Abbady A.-Q.,
RA   Jeanblanc M., Muller C.D., Rochette-Egly C., Mousli M.;
RT   "Phosphorylation of ICBP90 by protein kinase A enhances topoisomerase
RT   IIalpha expression.";
RL   Biochem. Biophys. Res. Commun. 319:590-595(2004).
RN   [12]
RP   INDUCTION, UBIQUITINATION, AND FUNCTION.
RX   PubMed=15009091; DOI=10.1111/j.1356-9597.2004.00710.x;
RA   Arima Y., Hirota T., Bronner C., Mousli M., Fujiwara T., Niwa S.,
RA   Ishikawa H., Saya H.;
RT   "Down-regulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1-
RT   dependent DNA-damage checkpoint signals contributes to cell cycle
RT   arrest at G1/S transition.";
RL   Genes Cells 9:131-142(2004).
RN   [13]
RP   FUNCTION, INDUCTION, TISSUE SPECIFICITY, DNA-BINDING, AND INTERACTION
RP   WITH HDAC1 AND UHRF1BP1.
RX   PubMed=15361834; DOI=10.1038/sj.onc.1208053;
RA   Unoki M., Nishidate T., Nakamura Y.;
RT   "ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG
RT   through its SRA domain.";
RL   Oncogene 23:7601-7610(2004).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-287 AND SER-639, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-639, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [16]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH DNMT1.
RX   PubMed=17673620; DOI=10.1126/science.1147939;
RA   Bostick M., Kim J.K., Esteve P.O., Clark A., Pradhan S.,
RA   Jacobsen S.E.;
RT   "UHRF1 plays a role in maintaining DNA methylation in mammalian
RT   cells.";
RL   Science 317:1760-1764(2007).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-287, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [18]
RP   FUNCTION, SUBCELLULAR LOCATION, AND AUTOUBIQUITINATION.
RX   PubMed=17967883; DOI=10.1128/MCB.01598-07;
RA   Karagianni P., Amazit L., Qin J., Wong J.;
RT   "ICBP90, a novel methyl K9 H3 binding protein linking protein
RT   ubiquitination with heterochromatin formation.";
RL   Mol. Cell. Biol. 28:705-717(2008).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-76; SER-91 AND SER-707,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [20]
RP   INVOLVEMENT IN CANCER.
RX   PubMed=19491893; DOI=10.1038/sj.bjc.6605123;
RA   Unoki M., Kelly J.D., Neal D.E., Ponder B.A., Nakamura Y.,
RA   Hamamoto R.;
RT   "UHRF1 is a novel molecular marker for diagnosis and the prognosis of
RT   bladder cancer.";
RL   Br. J. Cancer 101:98-105(2009).
RN   [21]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH EHMT2.
RX   PubMed=19056828; DOI=10.1093/nar/gkn961;
RA   Kim J.K., Esteve P.O., Jacobsen S.E., Pradhan S.;
RT   "UHRF1 binds G9a and participates in p21 transcriptional regulation in
RT   mammalian cells.";
RL   Nucleic Acids Res. 37:493-505(2009).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-287, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [23]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-399 AND LYS-546, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [24]
RP   MUTAGENESIS OF TYR-188 AND TYR-191.
RX   PubMed=20026581; DOI=10.1093/nar/gkp1152;
RA   Rottach A., Frauer C., Pichler G., Bonapace I.M., Spada F.,
RA   Leonhardt H.;
RT   "The multi-domain protein Np95 connects DNA methylation and histone
RT   modification.";
RL   Nucleic Acids Res. 38:1796-1804(2010).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-76; SER-287; SER-639 AND
RP   SER-707, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [27]
RP   FUNCTION, AUTOUBIQUITINATION, DEUBIQUITINATION BY USP7, AND
RP   INTERACTION WITH USP7 AND DNMT1.
RX   PubMed=21745816; DOI=10.1093/nar/gkr528;
RA   Felle M., Joppien S., Nemeth A., Diermeier S., Thalhammer V.,
RA   Dobner T., Kremmer E., Kappler R., Langst G.;
RT   "The USP7/Dnmt1 complex stimulates the DNA methylation activity of
RT   Dnmt1 and regulates the stability of UHRF1.";
RL   Nucleic Acids Res. 39:8355-8365(2011).
RN   [28]
RP   HYDROXYMETHYLCYTOSINE-BINDING.
RX   PubMed=21731699; DOI=10.1371/journal.pone.0021306;
RA   Frauer C., Hoffmann T., Bultmann S., Casa V., Cardoso M.C., Antes I.,
RA   Leonhardt H.;
RT   "Recognition of 5-hydroxymethylcytosine by the Uhrf1 SRA domain.";
RL   PLoS ONE 6:E21306-E21306(2011).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-287 AND SER-651, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-76; SER-91; SER-287;
RP   SER-368; SER-639; SER-707 AND SER-709, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [31]
RP   FUNCTION, INTERACTION WITH PML, AND MUTAGENESIS OF HIS-741.
RX   PubMed=22945642; DOI=10.1038/onc.2012.406;
RA   Guan D., Factor D., Liu Y., Wang Z., Kao H.Y.;
RT   "The epigenetic regulator UHRF1 promotes ubiquitination-mediated
RT   degradation of the tumor-suppressor protein promyelocytic leukemia
RT   protein.";
RL   Oncogene 32:3819-3828(2013).
RN   [32]
RP   INVOLVEMENT IN CANCER.
RX   PubMed=22286757; DOI=10.1038/onc.2012.3;
RA   Sabatino L., Fucci A., Pancione M., Carafa V., Nebbioso A.,
RA   Pistore C., Babbio F., Votino C., Laudanna C., Ceccarelli M.,
RA   Altucci L., Bonapace I.M., Colantuoni V.;
RT   "UHRF1 coordinates peroxisome proliferator activated receptor gamma
RT   (PPARG) epigenetic silencing and mediates colorectal cancer
RT   progression.";
RL   Oncogene 31:5061-5072(2012).
RN   [33]
RP   INVOLVEMENT IN CANCER.
RX   PubMed=22330138; DOI=10.1038/onc.2011.641;
RA   Babbio F., Pistore C., Curti L., Castiglioni I., Kunderfranco P.,
RA   Brino L., Oudet P., Seiler R., Thalman G.N., Roggero E., Sarti M.,
RA   Pinton S., Mello-Grand M., Chiorino G., Catapano C.V., Carbone G.M.,
RA   Bonapace I.M.;
RT   "The SRA protein UHRF1 promotes epigenetic crosstalks and is involved
RT   in prostate cancer progression.";
RL   Oncogene 31:4878-4887(2012).
RN   [34]
RP   AUTOUBIQUITINATION, DEUBIQUITINATION BY USP7, INTERACTION WITH USP7,
RP   PHOSPHORYLATION AT SER-639, AND MUTAGENESIS OF SER-639.
RX   PubMed=22411829; DOI=10.1073/pnas.1116349109;
RA   Ma H., Chen H., Guo X., Wang Z., Sowa M.E., Zheng L., Hu S., Zeng P.,
RA   Guo R., Diao J., Lan F., Harper J.W., Shi Y.G., Xu Y., Shi Y.;
RT   "M phase phosphorylation of the epigenetic regulator UHRF1 regulates
RT   its physical association with the deubiquitylase USP7 and stability.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:4828-4833(2012).
RN   [35]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-385; LYS-546 AND LYS-670,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 1-76.
RG   Structural genomics consortium (SGC);
RT   "Ubiquitin-like domain of human nuclear zinc finger protein NP95.";
RL   Submitted (JAN-2006) to the PDB data bank.
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 408-643.
RX   PubMed=18931436; DOI=10.1107/S1744309108027462;
RA   Delagoutte B., Lallous N., Birck C., Oudet P., Samama J.P.;
RT   "Expression, purification, crystallization and preliminary
RT   crystallographic study of the SRA domain of the human UHRF1 protein.";
RL   Acta Crystallogr. F 64:922-925(2008).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 414-617, AND MUTAGENESIS OF
RP   ARG-433; ARG-443; TYR-466 AND ARG-491.
RX   PubMed=18945682; DOI=10.1074/jbc.C800169200;
RA   Qian C., Li S., Jakoncic J., Zeng L., Walsh M.J., Zhou M.M.;
RT   "Structure and hemimethylated CpG binding of the SRA domain from human
RT   UHRF1.";
RL   J. Biol. Chem. 283:34490-34494(2008).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 414-617 IN COMPLEX WITH
RP   HEMIMETHYLATED DNA, AND MUTAGENESIS OF GLY-448; ASN-489 AND ARG-491.
RX   PubMed=18772889; DOI=10.1038/nature07273;
RA   Avvakumov G.V., Walker J.R., Xue S., Li Y., Duan S., Bronner C.,
RA   Arrowsmith C.H., Dhe-Paganon S.;
RT   "Structural basis for recognition of hemi-methylated DNA by the SRA
RT   domain of human UHRF1.";
RL   Nature 455:822-825(2008).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 298-366, AND MUTAGENESIS OF
RP   ASP-334 AND ASP-337.
RX   PubMed=21808300; DOI=10.1038/cr.2011.124;
RA   Hu L., Li Z., Wang P., Lin Y., Xu Y.;
RT   "Crystal structure of PHD domain of UHRF1 and insights into
RT   recognition of unmodified histone H3 arginine residue 2.";
RL   Cell Res. 21:1374-1378(2011).
RN   [41]
RP   STRUCTURE BY NMR OF 298-366, AND MUTAGENESIS OF ASP-334 AND ASP-337.
RX   PubMed=21808299; DOI=10.1038/cr.2011.123;
RA   Wang C., Shen J., Yang Z., Chen P., Zhao B., Hu W., Lan W., Tong X.,
RA   Wu H., Li G., Cao C.;
RT   "Structural basis for site-specific reading of unmodified R2 of
RT   histone H3 tail by UHRF1 PHD finger.";
RL   Cell Res. 21:1379-1382(2011).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 126-285, STRUCTURE BY NMR OF
RP   126-285, AND MUTAGENESIS OF ASP-142; ASP-145; PHE-152; GLU-153;
RP   TYR-188 AND ASP-190.
RX   PubMed=21489993; DOI=10.1074/jbc.M111.234104;
RA   Nady N., Lemak A., Walker J.R., Avvakumov G.V., Kareta M.S.,
RA   Achour M., Xue S., Duan S., Allali-Hassani A., Zuo X., Wang Y.X.,
RA   Bronner C., Chedin F., Arrowsmith C.H., Dhe-Paganon S.;
RT   "Recognition of multivalent histone states associated with
RT   heterochromatin by UHRF1 protein.";
RL   J. Biol. Chem. 286:24300-24311(2011).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 298-367 IN COMPLEX WITH ZINC
RP   AND HISTONE H3 PEPTIDE, FUNCTION, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF 334-ASP-GLU-335.
RX   PubMed=21777816; DOI=10.1016/j.molcel.2011.07.006;
RA   Rajakumara E., Wang Z., Ma H., Hu L., Chen H., Lin Y., Guo R., Wu F.,
RA   Li H., Lan F., Shi Y.G., Xu Y., Patel D.J., Shi Y.;
RT   "PHD finger recognition of unmodified histone H3R2 links UHRF1 to
RT   regulation of euchromatic gene expression.";
RL   Mol. Cell 43:275-284(2011).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS) OF 314-367, AND MUTAGENESIS OF
RP   GLN-330; ASP-334 AND ASP-337.
RX   PubMed=22096602; DOI=10.1371/journal.pone.0027599;
RA   Lallous N., Legrand P., McEwen A.G., Ramon-Maiques S., Samama J.P.,
RA   Birck C.;
RT   "The PHD finger of human UHRF1 reveals a new subgroup of unmethylated
RT   histone H3 tail readers.";
RL   PLoS ONE 6:E27599-E27599(2011).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 299-364 IN COMPLEX WITH
RP   HISTONE H3 PEPTIDE.
RX   PubMed=22100450; DOI=10.1016/j.jmb.2011.11.012;
RA   Xie S., Jakoncic J., Qian C.;
RT   "UHRF1 double tudor domain and the adjacent PHD finger act together to
RT   recognize K9me3-containing histone H3 tail.";
RL   J. Mol. Biol. 415:318-328(2012).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 134-367 IN COMPLEX WITH ZINC
RP   AND HISTONE H3 PEPTIDE, PHOSPHORYLATION AT SER-298, AND MUTAGENESIS OF
RP   295-ARG-ARG-296.
RX   PubMed=22837395; DOI=10.1073/pnas.1203701109;
RA   Arita K., Isogai S., Oda T., Unoki M., Sugita K., Sekiyama N.,
RA   Kuwata K., Hamamoto R., Tochio H., Sato M., Ariyoshi M., Shirakawa M.;
RT   "Recognition of modification status on a histone H3 tail by linked
RT   histone reader modules of the epigenetic regulator UHRF1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12950-12955(2012).
CC   -!- FUNCTION: Multidomain protein that acts as a key epigenetic
CC       regulator by bridging DNA methylation and chromatin modification.
CC       Specifically recognizes and binds hemimethylated DNA at
CC       replication forks via its YDG domain and recruits DNMT1
CC       methyltransferase to ensure faithful propagation of the DNA
CC       methylation patterns through DNA replication. In addition to its
CC       role in maintenance of DNA methylation, also plays a key role in
CC       chromatin modification: through its tudor-like regions and PHD-
CC       type zinc fingers, specifically recognizes and binds histone H3
CC       trimethylated at 'Lys-9' (H3K9me3) and unmethylated at 'Arg-2'
CC       (H3R2me0), respectively, and recruits chromatin proteins. Enriched
CC       in pericentric heterochromatin where it recruits different
CC       chromatin modifiers required for this chromatin replication. Also
CC       localizes to euchromatic regions where it negatively regulates
CC       transcription possibly by impacting DNA methylation and histone
CC       modifications. Has E3 ubiquitin-protein ligase activity by
CC       mediating the ubiquitination of target proteins such as histone H3
CC       and PML. It is still unclear how E3 ubiquitin-protein ligase
CC       activity is related to its role in chromatin in vivo. May be
CC       involved in DNA repair. {ECO:0000269|PubMed:10646863,
CC       ECO:0000269|PubMed:15009091, ECO:0000269|PubMed:15361834,
CC       ECO:0000269|PubMed:17673620, ECO:0000269|PubMed:17967883,
CC       ECO:0000269|PubMed:19056828, ECO:0000269|PubMed:21745816,
CC       ECO:0000269|PubMed:21777816, ECO:0000269|PubMed:22945642}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts with DNMT3A and DNMT3B (By similarity).
CC       Interacts with DNMT1; the interaction is direct. Interacts with
CC       USP7; leading to its deubiquitination. Interacts with histone H3.
CC       Interacts with HDAC1, but not with HDAC2. Interacts with UHRF1BP1.
CC       Interacts with PML. Interacts with EHMT2. Binds hemimethylated CpG
CC       containing oligonucleotides. {ECO:0000250,
CC       ECO:0000269|PubMed:15361834, ECO:0000269|PubMed:17673620,
CC       ECO:0000269|PubMed:18772889, ECO:0000269|PubMed:19056828,
CC       ECO:0000269|PubMed:21745816, ECO:0000269|PubMed:21777816,
CC       ECO:0000269|PubMed:22100450, ECO:0000269|PubMed:22411829,
CC       ECO:0000269|PubMed:22837395, ECO:0000269|PubMed:22945642}.
CC   -!- INTERACTION:
CC       P26358:DNMT1; NbExp=12; IntAct=EBI-1548946, EBI-719459;
CC       Q9Y6K1:DNMT3A; NbExp=7; IntAct=EBI-1548946, EBI-923653;
CC       Q9UBC3:DNMT3B; NbExp=7; IntAct=EBI-1548946, EBI-80125;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-
CC       ProRule:PRU00358, ECO:0000269|PubMed:10646863,
CC       ECO:0000269|PubMed:17673620, ECO:0000269|PubMed:17967883,
CC       ECO:0000269|PubMed:19056828, ECO:0000269|PubMed:21777816}.
CC       Note=Localizes to replication foci. Enriched in pericentric
CC       heterochromatin. Also localizes to euchromatic regions.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q96T88-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q96T88-2; Sequence=VSP_044394;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in thymus, bone marrow, testis, lung
CC       and heart. Overexpressed in breast cancer.
CC       {ECO:0000269|PubMed:10646863, ECO:0000269|PubMed:12838312,
CC       ECO:0000269|PubMed:15361834}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in fetal thymus, liver and kidney.
CC       {ECO:0000269|PubMed:10646863}.
CC   -!- INDUCTION: Up-regulated in proliferating cells, and down-regulated
CC       in quiescent cells. Down-regulated upon adriamycin-induced DNA
CC       damage, in a p53/TP53 and CDKN1A-dependent way. Induced by E2F1
CC       transcription factor. {ECO:0000269|PubMed:10646863,
CC       ECO:0000269|PubMed:12838312, ECO:0000269|PubMed:15009091,
CC       ECO:0000269|PubMed:15361834}.
CC   -!- DOMAIN: The tudor-like regions specifically recognize and bind
CC       histone H3 unmethylated at 'Arg-2' (H3R2me0), while the PHD-type
CC       zinc finger specifically recognizes and binds histone H3
CC       trimethylated at 'Lys-9' (H3K9me3). The tudor-like regions
CC       simultaneously recognizes H3K9me3 through a conserved aromatic
CC       cage in the first tudor-like subdomain and unmodified H3K4
CC       (H3K4me0) within a groove between the tandem subdomains
CC       (PubMed:21489993, PubMed:21777816 and PubMed:22100450). The linker
CC       region plays a role in the formation of a histone H3-binding hole
CC       between the reader modules formed by the tudor-like regions and
CC       the PHD-type zinc finger by making extended contacts with the
CC       tandem tudor-like regions (PubMed:22837395).
CC       {ECO:0000269|PubMed:22837395}.
CC   -!- DOMAIN: The YDG domain (also named SRA domain) specifically
CC       recognizes and binds hemimethylated DNA at replication forks (DNA
CC       that is only methylated on the mother strand of replicating DNA)
CC       (PubMed:17673620). It contains a binding pocket that accommodates
CC       the 5-methylcytosine that is flipped out of the duplex DNA. 2
CC       specialized loops reach through the resulting gap in the DNA from
CC       both the major and the minor grooves to read the other 3 bases of
CC       the CpG duplex. The major groove loop confers both specificity for
CC       the CpG dinucleotide and discrimination against methylation of
CC       deoxycytidine of the complementary strand (PubMed:18772889). The
CC       YDG domain also recognizes and binds 5-hydroxymethylcytosine
CC       (5hmC) (PubMed:21731699). {ECO:0000269|PubMed:17673620,
CC       ECO:0000269|PubMed:18772889, ECO:0000269|PubMed:21731699}.
CC   -!- DOMAIN: The RING finger is required for ubiquitin ligase activity.
CC       {ECO:0000250}.
CC   -!- PTM: Phosphorylation at Ser-298 of the linker region decreases the
CC       binding to H3K9me3. Phosphorylation at Ser-639 by CDK1 during M
CC       phase impairs interaction with USP7, preventing deubiquitination
CC       and leading to degradation by the proteasome.
CC       {ECO:0000269|PubMed:15178447, ECO:0000269|PubMed:22411829,
CC       ECO:0000269|PubMed:22837395}.
CC   -!- PTM: Ubiquitinated; which leads to proteasomal degradation.
CC       Autoubiquitinated; interaction with USP7 leads to deubiquitination
CC       and prevents degradation. Ubiquitination and degradation takes
CC       place during M phase, when phosphorylation at Ser-639 prevents
CC       intereaction with USP7 and subsequent deubiquitination.
CC       Polyubiquitination may be stimulated by DNA damage.
CC       {ECO:0000269|PubMed:15009091, ECO:0000269|PubMed:17967883,
CC       ECO:0000269|PubMed:21745816, ECO:0000269|PubMed:22411829}.
CC   -!- DISEASE: Note=Defects in UHRF1 may be a cause of cancers.
CC       Overexpressed in many different forms of human cancers, including
CC       bladder, breast, cervical, colorectal and prostate cancers, as
CC       well as pancreatic adenocarcinomas, rhabdomyosarcomas and gliomas.
CC       Plays an important role in the correlation of histone modification
CC       and gene silencing in cancer progression. Expression is associated
CC       with a poor prognosis in patients with various cancers, suggesting
CC       that it participates in cancer progression.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB15177.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/uhrf1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF129507; AAF28469.1; -; mRNA.
DR   EMBL; AB177623; BAF36719.1; -; mRNA.
DR   EMBL; AB177624; BAF36720.1; -; mRNA.
DR   EMBL; AB075601; BAC20576.1; -; mRNA.
DR   EMBL; AF274048; AAK55744.1; -; mRNA.
DR   EMBL; EF560733; ABQ59043.1; -; mRNA.
DR   EMBL; AK025578; BAB15177.1; ALT_INIT; mRNA.
DR   EMBL; AK289389; BAF82078.1; -; mRNA.
DR   EMBL; AK314579; BAG37156.1; -; mRNA.
DR   EMBL; AY787925; AAV40831.1; -; Genomic_DNA.
DR   EMBL; AC027319; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC053467; AAF64067.1; -; Genomic_DNA.
DR   EMBL; CH471139; EAW69187.1; -; Genomic_DNA.
DR   EMBL; BC113875; AAI13876.2; -; mRNA.
DR   CCDS; CCDS74262.1; -. [Q96T88-2]
DR   CCDS; CCDS74263.1; -. [Q96T88-1]
DR   RefSeq; NP_001041666.1; NM_001048201.2. [Q96T88-1]
DR   RefSeq; NP_001276979.1; NM_001290050.1. [Q96T88-1]
DR   RefSeq; NP_001276980.1; NM_001290051.1. [Q96T88-1]
DR   RefSeq; NP_001276981.1; NM_001290052.1. [Q96T88-1]
DR   RefSeq; NP_037414.3; NM_013282.4.
DR   UniGene; Hs.108106; -.
DR   PDB; 2FAZ; X-ray; 2.00 A; A/B=1-76.
DR   PDB; 2L3R; NMR; -; A=126-285.
DR   PDB; 2LGG; NMR; -; A=298-366.
DR   PDB; 2LGK; NMR; -; A=298-366.
DR   PDB; 2LGL; NMR; -; A=298-366.
DR   PDB; 2PB7; X-ray; 1.90 A; A=408-643.
DR   PDB; 3ASK; X-ray; 2.90 A; A/B/C/D=134-367.
DR   PDB; 3ASL; X-ray; 1.41 A; A=298-367.
DR   PDB; 3BI7; X-ray; 1.70 A; A=414-617.
DR   PDB; 3CLZ; X-ray; 2.20 A; A/B/C/D=414-617.
DR   PDB; 3DB3; X-ray; 2.40 A; A=126-285.
DR   PDB; 3DB4; X-ray; 2.40 A; A=126-285.
DR   PDB; 3DWH; X-ray; 1.95 A; A=414-617.
DR   PDB; 3FL2; X-ray; 1.75 A; A=672-793.
DR   PDB; 3SHB; X-ray; 1.80 A; A=298-366.
DR   PDB; 3SOU; X-ray; 1.80 A; A/B=298-367.
DR   PDB; 3SOW; X-ray; 1.95 A; A/B=298-367.
DR   PDB; 3SOX; X-ray; 2.65 A; A/B=298-367.
DR   PDB; 3T6R; X-ray; 1.95 A; A/B=299-364.
DR   PDB; 3ZVY; X-ray; 1.95 A; A/B=296-367.
DR   PDB; 3ZVZ; X-ray; 1.45 A; B=314-367.
DR   PDB; 4GY5; X-ray; 2.96 A; A/B/C/D=134-366.
DR   PDB; 4QQD; X-ray; 2.28 A; A/B=126-285.
DR   PDB; 5C6D; X-ray; 2.29 A; C/D=634-665.
DR   PDB; 5IAY; NMR; -; A=134-285, B=642-657.
DR   PDBsum; 2FAZ; -.
DR   PDBsum; 2L3R; -.
DR   PDBsum; 2LGG; -.
DR   PDBsum; 2LGK; -.
DR   PDBsum; 2LGL; -.
DR   PDBsum; 2PB7; -.
DR   PDBsum; 3ASK; -.
DR   PDBsum; 3ASL; -.
DR   PDBsum; 3BI7; -.
DR   PDBsum; 3CLZ; -.
DR   PDBsum; 3DB3; -.
DR   PDBsum; 3DB4; -.
DR   PDBsum; 3DWH; -.
DR   PDBsum; 3FL2; -.
DR   PDBsum; 3SHB; -.
DR   PDBsum; 3SOU; -.
DR   PDBsum; 3SOW; -.
DR   PDBsum; 3SOX; -.
DR   PDBsum; 3T6R; -.
DR   PDBsum; 3ZVY; -.
DR   PDBsum; 3ZVZ; -.
DR   PDBsum; 4GY5; -.
DR   PDBsum; 4QQD; -.
DR   PDBsum; 5C6D; -.
DR   PDBsum; 5IAY; -.
DR   ProteinModelPortal; Q96T88; -.
DR   SMR; Q96T88; -.
DR   BioGrid; 118893; 68.
DR   IntAct; Q96T88; 15.
DR   MINT; MINT-2815626; -.
DR   BindingDB; Q96T88; -.
DR   ChEMBL; CHEMBL2424510; -.
DR   iPTMnet; Q96T88; -.
DR   PhosphoSitePlus; Q96T88; -.
DR   BioMuta; UHRF1; -.
DR   DMDM; 67462077; -.
DR   EPD; Q96T88; -.
DR   MaxQB; Q96T88; -.
DR   PeptideAtlas; Q96T88; -.
DR   PRIDE; Q96T88; -.
DR   DNASU; 29128; -.
DR   Ensembl; ENST00000612630; ENSP00000484739; ENSG00000276043. [Q96T88-1]
DR   Ensembl; ENST00000615884; ENSP00000478601; ENSG00000276043. [Q96T88-1]
DR   Ensembl; ENST00000616255; ENSP00000478348; ENSG00000276043. [Q96T88-1]
DR   Ensembl; ENST00000624301; ENSP00000485604; ENSG00000276043. [Q96T88-1]
DR   GeneID; 29128; -.
DR   KEGG; hsa:29128; -.
DR   UCSC; uc032hkj.2; human. [Q96T88-1]
DR   CTD; 29128; -.
DR   DisGeNET; 29128; -.
DR   GeneCards; UHRF1; -.
DR   HGNC; HGNC:12556; UHRF1.
DR   HPA; HPA049408; -.
DR   MIM; 607990; gene.
DR   neXtProt; NX_Q96T88; -.
DR   OpenTargets; ENSG00000276043; -.
DR   PharmGKB; PA37196; -.
DR   GeneTree; ENSGT00390000008296; -.
DR   HOGENOM; HOG000124662; -.
DR   HOVERGEN; HBG059298; -.
DR   InParanoid; Q96T88; -.
DR   KO; K10638; -.
DR   PhylomeDB; Q96T88; -.
DR   Reactome; R-HSA-5334118; DNA methylation.
DR   SignaLink; Q96T88; -.
DR   SIGNOR; Q96T88; -.
DR   UniPathway; UPA00143; -.
DR   EvolutionaryTrace; Q96T88; -.
DR   GeneWiki; UHRF1; -.
DR   GenomeRNAi; 29128; -.
DR   PRO; PR:Q96T88; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   CleanEx; HS_UHRF1; -.
DR   ExpressionAtlas; Q96T88; baseline and differential.
DR   Genevisible; Q96T88; HS.
DR   GO; GO:0000791; C:euchromatin; IDA:UniProtKB.
DR   GO; GO:0000792; C:heterochromatin; IDA:UniProtKB.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:UniProtKB.
DR   GO; GO:0005720; C:nuclear heterochromatin; IBA:GO_Central.
DR   GO; GO:0016363; C:nuclear matrix; ISS:BHF-UCL.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0005657; C:replication fork; IDA:UniProtKB.
DR   GO; GO:0000987; F:core promoter proximal region sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:0044729; F:hemi-methylated DNA-binding; IDA:UniProtKB.
DR   GO; GO:0042393; F:histone binding; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; ISS:BHF-UCL.
DR   GO; GO:0008327; F:methyl-CpG binding; IDA:UniProtKB.
DR   GO; GO:0035064; F:methylated histone binding; IDA:UniProtKB.
DR   GO; GO:0031493; F:nucleosomal histone binding; ISS:BHF-UCL.
DR   GO; GO:0003700; F:transcription factor activity, sequence-specific DNA binding; TAS:ProtInc.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; ISS:BHF-UCL.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0008283; P:cell proliferation; IEP:BHF-UCL.
DR   GO; GO:0006281; P:DNA repair; IEA:UniProtKB-KW.
DR   GO; GO:0010390; P:histone monoubiquitination; ISS:BHF-UCL.
DR   GO; GO:0016574; P:histone ubiquitination; IDA:UniProtKB.
DR   GO; GO:0010216; P:maintenance of DNA methylation; IMP:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0032270; P:positive regulation of cellular protein metabolic process; IDA:BHF-UCL.
DR   GO; GO:2000373; P:positive regulation of DNA topoisomerase (ATP-hydrolyzing) activity; IC:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IC:BHF-UCL.
DR   GO; GO:0051865; P:protein autoubiquitination; IDA:UniProtKB.
DR   GO; GO:0042787; P:protein ubiquitination involved in ubiquitin-dependent protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0090308; P:regulation of methylation-dependent chromatin silencing; IBA:GO_Central.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   CDD; cd00162; RING; 1.
DR   Gene3D; 2.30.280.10; -; 1.
DR   Gene3D; 2.30.30.30; -; 1.
DR   Gene3D; 3.30.40.10; -; 2.
DR   InterPro; IPR015947; PUA-like_domain.
DR   InterPro; IPR014722; Rib_L2_dom2.
DR   InterPro; IPR003105; SRA_YDG.
DR   InterPro; IPR021991; TTD_dom.
DR   InterPro; IPR029071; Ubiquitin-rel_dom.
DR   InterPro; IPR000626; Ubiquitin_dom.
DR   InterPro; IPR011011; Znf_FYVE_PHD.
DR   InterPro; IPR001965; Znf_PHD.
DR   InterPro; IPR019787; Znf_PHD-finger.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   Pfam; PF00628; PHD; 1.
DR   Pfam; PF02182; SAD_SRA; 1.
DR   Pfam; PF12148; TTD; 1.
DR   Pfam; PF00240; ubiquitin; 1.
DR   SMART; SM00249; PHD; 1.
DR   SMART; SM00184; RING; 2.
DR   SMART; SM00466; SRA; 1.
DR   SMART; SM00213; UBQ; 1.
DR   SUPFAM; SSF54236; SSF54236; 1.
DR   SUPFAM; SSF57903; SSF57903; 1.
DR   SUPFAM; SSF88697; SSF88697; 1.
DR   PROSITE; PS50053; UBIQUITIN_2; 1.
DR   PROSITE; PS51015; YDG; 1.
DR   PROSITE; PS01359; ZF_PHD_1; 1.
DR   PROSITE; PS50016; ZF_PHD_2; 1.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Cell cycle;
KW   Chromatin regulator; Complete proteome; DNA damage; DNA repair;
KW   DNA-binding; Isopeptide bond; Metal-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat; Repressor; Transcription;
KW   Transcription regulation; Transferase; Ubl conjugation;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN         1    793       E3 ubiquitin-protein ligase UHRF1.
FT                                /FTId=PRO_0000056144.
FT   DOMAIN        1     78       Ubiquitin-like. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00214}.
FT   DOMAIN      419    582       YDG. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00358}.
FT   ZN_FING     310    366       PHD-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00146}.
FT   ZN_FING     724    763       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   REGION      133    209       Tudor-like 1.
FT   REGION      216    283       Tudor-like 2.
FT   REGION      296    301       Linker.
FT   REGION      333    337       Histone H3R2me0 binding.
FT   REGION      353    355       Histone H3R2me0 binding.
FT   REGION      445    446       Required to promote base flipping.
FT                                {ECO:0000250}.
FT   REGION      463    464       Methylcytosine binding.
FT   REGION      466    469       Required for formation of a 5-
FT                                methylcytosine-binding pocket.
FT   REGION      478    481       Required for formation of a 5-
FT                                methylcytosine-binding pocket.
FT   BINDING     316    316       Histone H3K4me0.
FT   BINDING     327    327       Histone H3R2me0.
FT   BINDING     330    330       Histone H3R2me0.
FT   BINDING     469    469       Methylcytosine.
FT   SITE        479    479       Required to confer preferential
FT                                recognition of cytosine over thymine.
FT   SITE        489    489       Required to discriminate between
FT                                hemimethylated DNA versus symmetrically
FT                                methylated DNA.
FT   SITE        491    491       Required for affinity and specificity for
FT                                5-mCpG sequence.
FT   MOD_RES      76     76       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      91     91       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      95     95       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q7TPK1}.
FT   MOD_RES     165    165       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8VDF2}.
FT   MOD_RES     287    287       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18220336,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     298    298       Phosphoserine; by PKA.
FT                                {ECO:0000269|PubMed:15178447,
FT                                ECO:0000269|PubMed:22837395}.
FT   MOD_RES     368    368       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     399    399       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     546    546       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     639    639       Phosphoserine; by CDK1.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:22411829}.
FT   MOD_RES     651    651       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES     707    707       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     709    709       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   CROSSLNK    385    385       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25218447}.
FT   CROSSLNK    546    546       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2);
FT                                alternate. {ECO:0000244|PubMed:25218447}.
FT   CROSSLNK    670    670       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25218447}.
FT   VAR_SEQ       1      1       M -> MGVFAVPPLSSDTM (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_044394.
FT   VARIANT     240    240       D -> H (in dbSNP:rs17886098).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_022554.
FT   VARIANT     379    379       E -> K (in dbSNP:rs17885791).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_022555.
FT   VARIANT     638    638       A -> T (in dbSNP:rs17883331).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_022556.
FT   VARIANT     642    642       T -> M (in dbSNP:rs17884843).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_022557.
FT   VARIANT     713    713       L -> F (in dbSNP:rs17883563).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_022558.
FT   MUTAGEN     142    142       D->A: Impaired binding to histone H3
FT                                without affecting the protein folding;
FT                                when associated with A-153.
FT                                {ECO:0000269|PubMed:21489993}.
FT   MUTAGEN     145    145       D->A: Impaired binding to histone H3.
FT                                {ECO:0000269|PubMed:21489993}.
FT   MUTAGEN     152    152       F->A: Impaired binding to histone H3.
FT                                {ECO:0000269|PubMed:21489993}.
FT   MUTAGEN     153    153       E->A: Impaired binding to histone H3
FT                                without affecting the protein folding;
FT                                when associated with A-142.
FT                                {ECO:0000269|PubMed:21489993}.
FT   MUTAGEN     188    188       Y->A: Impaired binding to histone H3.
FT                                {ECO:0000269|PubMed:20026581,
FT                                ECO:0000269|PubMed:21489993}.
FT   MUTAGEN     190    190       D->A: Slightly impaired binding to
FT                                histone H3.
FT                                {ECO:0000269|PubMed:21489993}.
FT   MUTAGEN     191    191       Y->A: Impaired binding to histone H3.
FT                                {ECO:0000269|PubMed:20026581}.
FT   MUTAGEN     295    296       RR->AA: Disrupts the simultaneous binding
FT                                to H3R2me0 and H3K9me3.
FT                                {ECO:0000269|PubMed:22837395}.
FT   MUTAGEN     298    298       S->A: Diminishes phosphorylation by PKA.
FT                                {ECO:0000269|PubMed:15178447}.
FT   MUTAGEN     330    330       Q->A,K: Does not affect ability to bind
FT                                histone H3 peptide.
FT                                {ECO:0000269|PubMed:22096602}.
FT   MUTAGEN     334    335       DE->AA: Abolishes binding to histone H3.
FT                                {ECO:0000269|PubMed:21777816}.
FT   MUTAGEN     334    334       D->A: Impaired binding to histone H3.
FT                                {ECO:0000269|PubMed:21808299,
FT                                ECO:0000269|PubMed:21808300,
FT                                ECO:0000269|PubMed:22096602}.
FT   MUTAGEN     337    337       D->A: Impaired binding to histone H3.
FT                                {ECO:0000269|PubMed:21808299,
FT                                ECO:0000269|PubMed:21808300,
FT                                ECO:0000269|PubMed:22096602}.
FT   MUTAGEN     433    433       R->A: Does not affect ability to bind
FT                                DNA. {ECO:0000269|PubMed:18945682}.
FT   MUTAGEN     443    443       R->A: Decreased ability to bind DNA.
FT                                {ECO:0000269|PubMed:18945682}.
FT   MUTAGEN     448    448       G->D: Decreased affinity for DNA.
FT                                {ECO:0000269|PubMed:18772889}.
FT   MUTAGEN     466    466       Y->G: Decreased ability to bind DNA.
FT                                {ECO:0000269|PubMed:18945682}.
FT   MUTAGEN     469    469       D->G: Abolishes ability to bind
FT                                hemimethylated DNA.
FT   MUTAGEN     489    489       N->A: Abolishes specificity to
FT                                hemimethylated DNA.
FT                                {ECO:0000269|PubMed:18772889}.
FT   MUTAGEN     491    491       R->A: Decreased binding to methylated DNA
FT                                but does not affect ability to bind DNA.
FT                                {ECO:0000269|PubMed:18772889,
FT                                ECO:0000269|PubMed:18945682}.
FT   MUTAGEN     639    639       S->A: Prevents phosphorylation by CDK1
FT                                during M phase, leading to increased
FT                                stability. {ECO:0000269|PubMed:22411829}.
FT   MUTAGEN     639    639       S->D: Mimics phosphorylation; impaired
FT                                interaction with USP7, leading to
FT                                decreased stability.
FT                                {ECO:0000269|PubMed:22411829}.
FT   MUTAGEN     651    651       S->A: No effect on in vitro
FT                                phosphorylation by PKA.
FT                                {ECO:0000269|PubMed:15178447}.
FT   MUTAGEN     666    666       S->A: No effect on in vitro
FT                                phosphorylation by PKA.
FT                                {ECO:0000269|PubMed:15178447}.
FT   MUTAGEN     741    741       H->A: Abolishes E3 ubiquitin-protein
FT                                ligase activity.
FT                                {ECO:0000269|PubMed:22945642}.
FT   CONFLICT    383    383       K -> E (in Ref. 5; BAF82078).
FT                                {ECO:0000305}.
FT   CONFLICT    383    383       K -> N (in Ref. 1; AAF28469).
FT                                {ECO:0000305}.
FT   CONFLICT    457    457       A -> S (in Ref. 1; AAF28469).
FT                                {ECO:0000305}.
FT   CONFLICT    675    675       S -> N (in Ref. 5; BAF82078).
FT                                {ECO:0000305}.
FT   STRAND        1      7       {ECO:0000244|PDB:2FAZ}.
FT   STRAND       13     19       {ECO:0000244|PDB:2FAZ}.
FT   HELIX        25     36       {ECO:0000244|PDB:2FAZ}.
FT   HELIX        40     42       {ECO:0000244|PDB:2FAZ}.
FT   STRAND       43     47       {ECO:0000244|PDB:2FAZ}.
FT   TURN         58     62       {ECO:0000244|PDB:2FAZ}.
FT   STRAND       68     73       {ECO:0000244|PDB:2FAZ}.
FT   TURN        127    129       {ECO:0000244|PDB:2L3R}.
FT   STRAND      140    144       {ECO:0000244|PDB:4QQD}.
FT   TURN        146    148       {ECO:0000244|PDB:4QQD}.
FT   STRAND      151    161       {ECO:0000244|PDB:4QQD}.
FT   STRAND      164    167       {ECO:0000244|PDB:2L3R}.
FT   TURN        179    181       {ECO:0000244|PDB:2L3R}.
FT   STRAND      182    188       {ECO:0000244|PDB:4QQD}.
FT   HELIX       192    194       {ECO:0000244|PDB:4QQD}.
FT   STRAND      196    200       {ECO:0000244|PDB:4QQD}.
FT   HELIX       201    203       {ECO:0000244|PDB:4QQD}.
FT   STRAND      204    206       {ECO:0000244|PDB:4QQD}.
FT   STRAND      210    212       {ECO:0000244|PDB:2L3R}.
FT   HELIX       214    216       {ECO:0000244|PDB:4QQD}.
FT   STRAND      222    227       {ECO:0000244|PDB:4QQD}.
FT   STRAND      229    231       {ECO:0000244|PDB:4QQD}.
FT   STRAND      237    248       {ECO:0000244|PDB:4QQD}.
FT   STRAND      253    260       {ECO:0000244|PDB:4QQD}.
FT   STRAND      262    272       {ECO:0000244|PDB:4QQD}.
FT   HELIX       274    276       {ECO:0000244|PDB:2L3R}.
FT   STRAND      277    279       {ECO:0000244|PDB:2L3R}.
FT   STRAND      283    286       {ECO:0000244|PDB:3ASK}.
FT   TURN        303    307       {ECO:0000244|PDB:3ASL}.
FT   STRAND      309    311       {ECO:0000244|PDB:2LGG}.
FT   TURN        314    316       {ECO:0000244|PDB:3ASL}.
FT   TURN        319    321       {ECO:0000244|PDB:3ASL}.
FT   STRAND      323    325       {ECO:0000244|PDB:2LGL}.
FT   HELIX       327    329       {ECO:0000244|PDB:3ASL}.
FT   STRAND      330    332       {ECO:0000244|PDB:3ASL}.
FT   TURN        334    336       {ECO:0000244|PDB:3ASL}.
FT   STRAND      339    341       {ECO:0000244|PDB:3ASL}.
FT   HELIX       342    344       {ECO:0000244|PDB:3ASL}.
FT   STRAND      345    347       {ECO:0000244|PDB:3ASL}.
FT   STRAND      354    356       {ECO:0000244|PDB:3ASL}.
FT   TURN        361    363       {ECO:0000244|PDB:3ASL}.
FT   STRAND      417    419       {ECO:0000244|PDB:3DWH}.
FT   STRAND      429    432       {ECO:0000244|PDB:3BI7}.
FT   HELIX       433    438       {ECO:0000244|PDB:3BI7}.
FT   TURN        439    442       {ECO:0000244|PDB:3DWH}.
FT   STRAND      448    452       {ECO:0000244|PDB:3BI7}.
FT   TURN        453    455       {ECO:0000244|PDB:3BI7}.
FT   STRAND      456    462       {ECO:0000244|PDB:3BI7}.
FT   STRAND      473    479       {ECO:0000244|PDB:3BI7}.
FT   TURN        487    489       {ECO:0000244|PDB:3CLZ}.
FT   HELIX       503    511       {ECO:0000244|PDB:3BI7}.
FT   STRAND      512    514       {ECO:0000244|PDB:3BI7}.
FT   TURN        518    520       {ECO:0000244|PDB:3BI7}.
FT   HELIX       527    529       {ECO:0000244|PDB:3BI7}.
FT   STRAND      533    538       {ECO:0000244|PDB:3BI7}.
FT   HELIX       539    544       {ECO:0000244|PDB:3BI7}.
FT   STRAND      546    548       {ECO:0000244|PDB:3CLZ}.
FT   STRAND      550    568       {ECO:0000244|PDB:3BI7}.
FT   STRAND      572    582       {ECO:0000244|PDB:3BI7}.
FT   HELIX       592    601       {ECO:0000244|PDB:3BI7}.
FT   HELIX       611    617       {ECO:0000244|PDB:3BI7}.
FT   HELIX       678    686       {ECO:0000244|PDB:3FL2}.
FT   HELIX       688    690       {ECO:0000244|PDB:3FL2}.
FT   HELIX       691    699       {ECO:0000244|PDB:3FL2}.
FT   STRAND      706    708       {ECO:0000244|PDB:3FL2}.
FT   HELIX       710    721       {ECO:0000244|PDB:3FL2}.
FT   TURN        725    727       {ECO:0000244|PDB:3FL2}.
FT   STRAND      728    730       {ECO:0000244|PDB:3FL2}.
FT   STRAND      732    736       {ECO:0000244|PDB:3FL2}.
FT   STRAND      742    744       {ECO:0000244|PDB:3FL2}.
FT   HELIX       745    753       {ECO:0000244|PDB:3FL2}.
FT   TURN        760    762       {ECO:0000244|PDB:3FL2}.
FT   HELIX       776    785       {ECO:0000244|PDB:3FL2}.
FT   TURN        787    792       {ECO:0000244|PDB:3FL2}.
SQ   SEQUENCE   793 AA;  89814 MW;  E65B15657525C89F CRC64;
     MWIQVRTMDG RQTHTVDSLS RLTKVEELRR KIQELFHVEP GLQRLFYRGK QMEDGHTLFD
     YEVRLNDTIQ LLVRQSLVLP HSTKERDSEL SDTDSGCCLG QSESDKSSTH GEAAAETDSR
     PADEDMWDET ELGLYKVNEY VDARDTNMGA WFEAQVVRVT RKAPSRDEPC SSTSRPALEE
     DVIYHVKYDD YPENGVVQMN SRDVRARART IIKWQDLEVG QVVMLNYNPD NPKERGFWYD
     AEISRKRETR TARELYANVV LGDDSLNDCR IIFVDEVFKI ERPGEGSPMV DNPMRRKSGP
     SCKHCKDDVN RLCRVCACHL CGGRQDPDKQ LMCDECDMAF HIYCLDPPLS SVPSEDEWYC
     PECRNDASEV VLAGERLRES KKKAKMASAT SSSQRDWGKG MACVGRTKEC TIVPSNHYGP
     IPGIPVGTMW RFRVQVSESG VHRPHVAGIH GRSNDGAYSL VLAGGYEDDV DHGNFFTYTG
     SGGRDLSGNK RTAEQSCDQK LTNTNRALAL NCFAPINDQE GAEAKDWRSG KPVRVVRNVK
     GGKNSKYAPA EGNRYDGIYK VVKYWPEKGK SGFLVWRYLL RRDDDEPGPW TKEGKDRIKK
     LGLTMQYPEG YLEALANRER EKENSKREEE EQQEGGFASP RTGKGKWKRK SAGGGPSRAG
     SPRRTSKKTK VEPYSLTAQQ SSLIREDKSN AKLWNEVLAS LKDRPASGSP FQLFLSKVEE
     TFQCICCQEL VFRPITTVCQ HNVCKDCLDR SFRAQVFSCP ACRYDLGRSY AMQVNQPLQT
     VLNQLFPGYG NGR
//
